Novel antibody based binders derived from human immunoglobulins and camelid immunoglobulins have been described. These binders recognize and specifically bind Clostridium difficile toxin A and / or toxin B, and in some cases exhibit toxin neutralizing activity. These binders can be used to treat or prevent primary CDI and recurrent CDI. Such binders include Camelidae VHH peptide monomers, linked VHA group of H peptide monomers, a group bound to the Fc domain of the antibody VHH peptide monomers, and V molecules bound to IgG antibodiesHH peptide monomers.(FIG.
